IV treatments typically show faster results than oral supplements
Overall survival (OS) and disease-free survival (DFS) were analyzed and stratified based on GPX4-expression status of PTC tumors
Stacking decisions are made between patient and prescribing clinician based on individual response
Retatrutide, an investigational therapy being developed by Eli Lilly, is generating significant attention in the obesity and metabolic health space
Tranexamic acid interferes with the melanocyte-keratinocyte interaction instead, which makes it gentler but less potent, and better suited to sensitive skin and milder pigmentation
Moreover, the rising prevalence of obesity and type 2 diabetes (T2D) globally continues to significantly boost market demand, as GLP-1 agonists play an essential role in the treatment and management of these conditions